Adnkronos Rome, May 15 (Adnkronos Salute) – Ten years of innovation, research and concrete results. Ibsa Italy celebrates an important milestone: the 10th anniversary of Nahyco* Hybrid Technology, which has redefined the approach to aesthetic medicine. Launched in 2015, this innovative patented technology marked the company's entry into the field of regenerative aesthetic medicine, which aims to slow down the aging process and achieve aesthetic improvements through tissue regeneration, an area in which IBSA has been a pioneer since the beginning.
Thanks to technology, a new world of hyaluronic acid-based products has been born, represented by stable cooperative hybrid complexes (HCP), which have introduced the Profhilo* product line to the market. These complexes – explains a note – combine high and low molecular weight hyaluronic acid at a high concentration, offering unique properties that make them suitable for the regeneration of facial and body tissues.
The patented thermal process underlying the technology prolongs the permanence of hyaluronic acid in the tissues, without the need for chemical agents, and increases its concentration while maintaining a high safety profile and optimal physical properties of the product. "The innovative Nahyco* hybrid technology allows a proactive approach to rejuvenation, restores the functionality of the extracellular matrix and enhances the tissue regeneration process, acting on the different anatomical layers," said Antonello Tateo, head of the Plastic Surgery Unit at the Istituto Auxologico Italiano in Milan, noting that the system has "allowed us to redefine the standards of regenerative aesthetic medicine, integrating for the first time in a single treatment remodeling, firmness and improvement of tissue quality."
A technological evolution that reflects a paradigm shift observed in the field of aesthetic medicine: the focus has shifted from a transformative approach, focused on the single wrinkle or imperfection, to a qualitative and holistic approach, in which the patient is accompanied on a 360° regeneration path. Thanks to its constant research, over the last ten years Ibsa has developed a range of targeted solutions, designed to address the signs of aging based on the specific needs of different areas of the body and types of tissue. These solutions not only combat skin laxity on the face and body, but also act on various layers, from the dermis to the deeper structures.
"Ten years after their introduction on the market, Nahyco* technology and the Profhilo* line continue to inspire innovation in aesthetic medicine: the results obtained at the level of the dermis have prompted us to explore the application in deeper tissues, leading to the most recent formulation of the line dedicated to the restoration of adipose tissue, revealing a significant regenerative impact – stated Michela Zazzaron, aesthetic doctor and member of the Scientific Committee of Agorà – Furthermore, the proven tolerability and safety in the repeatability of the treatments” based on the technology allows us to preserve the integrity of the tissues, accompanying each patient on a tailor-made path, respectful of the uniqueness and characteristics of each individual".
This important milestone would not have been possible without the innovation that led to the foundation of Ibsa's aesthetic medicine division in 2005. "Our journey began with the idea of applying our consolidated experience in the use of hyaluronic acid, already successfully used in other therapeutic areas, to aesthetic medicine" – underlined Andrea Giori, Head of Preclinical & Clinical Research Ibsa – That initial spark started a research path that allowed us to develop cutting-edge technologies and innovative formulations, adopting new approaches that integrate aesthetic medicine with regenerative medicine and promoting a concept of beauty increasingly linked to global well-being. Nahyco* technology has allowed us to overcome the limits of traditional formulations, increasing the concentration of hyaluronic acid without compromising the manageability and injectability of the finished product".
Aesthetic medicine has undergone a profound transformation in recent decades, thanks to the advent of new technologies and innovative approaches, moving from an elite discipline to a widespread and increasingly accessible medical practice. "Aesthetic medicine used to be almost exclusively the prerogative of women between 35 and 60 years old - highlighted Emanuele Bartoletti, president of the Italian Society of Aesthetic Medicine (Sime) - Today, however, it is aimed at a much wider and more diversified public, which also includes young people from 18 years old up to people over eighty. This change, however, raises some critical issues: more and more often, people who are too young request aesthetic medicine treatments that they do not really need. At 18, it is fine to turn to aesthetic medicine to solve an acne problem, but not to have a lip job. It is essential to educate both the public and doctors to carefully evaluate requests, avoiding inappropriate requests. In fact, Me promotes preventive approaches even before corrective ones, with the aim of improving the quality of life and accompanying the patient on a harmonious and personalized path, guiding them towards truly informed choices".